2 assets in Vulvar Melanoma

Therapeutic assets addressing Vulvar Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Vulvar Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vulvar Melanoma	National Cancer Institute (NCI)	P2	CCC (53)